{"id":"W2159205789","doi":"10.1016/s0140-6736(06)69705-5","title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","year":2006,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3875,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Deutsche Diabetes Gesellschaft; Canada Research Chairs; Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Vildagliptin; Incretin; Exenatide; Liraglutide; Sitagliptin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Pharmacology; Glucagon-like peptide 1 receptor; Gastric emptying; Diabetes mellitus; Receptor; Agonist","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}